semaglutide type 1 diabetes GLP-1 Drugs and Diabetes: Less Insulin, Better Time in Range — What the Evidence GLP-1-based medications reduce body weight

Gut 2018

Ethical and technical challengessuch as immunogenicity risks in injectable formulations (e.g., PEGylated uricase), long-term biocompatibility of advanced materials, and scalability of nanofabrication processesdemand rigorous surveillance frameworks and cost-effective manufacturing strategies

Notably, that CD40 ligand and IL-4 stimulation led to increase of mitochondrial sSOX in AZD-5991 combination with CB-839 compared to unstimulated cells

doi: 10.1152/ajpcell.00599.2006

Zinman B, Inzucchi SE, Lachin JM, Wanner C, Ferrari R, Fitchett D, Bluhmki E, Hantel S, Kempthorne-Rawson J, Newman J, Johansen OE, Woerle HJ, Broedl UC